A Case of Castleman’s Disease with a Marked Infiltration of IgG4-Positive Cells in the Renal Interstitium
Abstract
:1. Introduction
2. Case Presentation
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Castleman, B.; Iverson, L.; Menendez, V.P. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 1956, 9, 822–830. [Google Scholar] [CrossRef]
- Fajgenbaum, D.C.; Uldrick, T.S.; Bagg, A.; Frank, D.; Wu, D.; Srkalovic, G.; Simpson, D.; Liu, A.Y.; Menke, D.; Chandrakasan, S. International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease. Blood J. Am. Soc. Hematol. 2017, 129, 1646–1657. [Google Scholar] [CrossRef]
- Zhou, T.; Wang, H.W.; Pittaluga, S.; Jaffe, E.S. Multicentric Castleman disease and the evolution of the concept. Pathologica 2021, 113, 339–353. [Google Scholar] [CrossRef]
- Fajgenbaum, D.C.; van Rhee, F.; Nabel, C.S. HHV-8-negative, idiopathic multicentric Castleman disease: Novel insights into biology, pathogenesis, and therapy. Blood J. Am. Soc. Hematol. 2014, 123, 2924–2933. [Google Scholar] [CrossRef]
- Liu, A.Y.; Nabel, C.S.; Finkelman, B.S.; Ruth, J.R.; Kurzrock, R.; van Rhee, F.; Krymskaya, V.P.; Kelleher, D.; Rubenstein, A.H.; Fajgenbaum, D.C. Idiopathic multicentric Castleman’s disease: A systematic literature review. Lancet Haematol. 2016, 3, e163–e175. [Google Scholar] [CrossRef]
- Dispenzieri, A.; Fajgenbaum, D.C. Overview of Castleman disease. Blood 2020, 135, 1353–1364. [Google Scholar] [CrossRef] [PubMed]
- Nishimoto, N.; Kanakura, Y.; Aozasa, K.; Johkoh, T.; Nakamura, M.; Nakano, S.; Nakano, N.; Ikeda, Y.; Sasaki, T.; Nishioka, K. Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005, 106, 2627–2632. [Google Scholar] [CrossRef] [PubMed]
- Van Rhee, F.; Wong, R.S.; Munshi, N.; Rossi, J.-F.; Ke, X.-Y.; Fosså, A.; Simpson, D.; Capra, M.; Liu, T.; Hsieh, R.K. Siltuximab for multicentric Castleman’s disease: A randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014, 15, 966–974. [Google Scholar] [CrossRef] [PubMed]
- Van Rhee, F.; Voorhees, P.; Dispenzieri, A.; Fosså, A.; Srkalovic, G.; Ide, M.; Munshi, N.; Schey, S.; Streetly, M.; Pierson, S.K. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood J. Am. Soc. Hematol. 2018, 132, 2115–2124. [Google Scholar] [CrossRef] [PubMed]
- Wu, Y.J.; Su, K.Y. Updates on the diagnosis and management of multicentric Castleman disease. Tzu Chi Med. J. 2021, 33, 22–28. [Google Scholar] [PubMed]
- Zen, Y.; Nakanuma, Y. IgG4-related disease: A cross-sectional study of 114 cases. Am. J. Surg. Pathol. 2010, 34, 1812–1819. [Google Scholar] [CrossRef]
- Sato, Y.; Kojima, M.; Takata, K.; Morito, T.; Asaoku, H.; Takeuchi, T.; Mizobuchi, K.; Fujihara, M.; Kuraoka, K.; Nakai, T.; et al. Systemic IgG4-related lymphadenopathy: A clinical and pathologic comparison to multicentric Castleman’s disease. Mod. Pathol. 2009, 22, 589–599. [Google Scholar] [CrossRef]
- Kamisawa, T.; Zen, Y.; Pillai, S.; Stone, J.H. IgG4-related disease. Lancet 2015, 385, 1460–1471. [Google Scholar] [CrossRef]
- Stone, J.H.; Zen, Y.; Deshpande, V. IgG4-related disease. N. Engl. J. Med. 2012, 366, 539–551. [Google Scholar] [CrossRef]
- Kamisawa, T.; Anjiki, H.; Egawa, N.; Kubota, N. Allergic manifestations in autoimmune pancreatitis. Eur. J. Gastroenterol. Hepatol. 2009, 21, 1136–1139. [Google Scholar] [CrossRef]
- Kamisawa, T.; Shimosegawa, T.; Okazaki, K.; Nishino, T.; Watanabe, H.; Kanno, A.; Okumura, F.; Nishikawa, T.; Kobayashi, K.; Ichiya, T. Standard steroid therapy for autoimmune pancreatitis. Gut 2009, 58, 1438–1439. [Google Scholar] [CrossRef]
- Sun, D.-P.; Chen, W.-M.; Wang, L.; Wang, Z.; Liang, J.-H.; Zhu, H.-Y.; Fan, L.; Wu, Y.-J.; Xu, W.; Li, J.-Y. Clinical characteristics and immunological abnormalities of Castleman disease complicated with autoimmune diseases. J. Cancer Res. Clin. Oncol. 2021, 147, 2107–2115. [Google Scholar] [CrossRef]
- Masaki, Y.; Matsui, S.; Saeki, T.; Tsuboi, H.; Hirata, S.; Izumi, Y.; Miyashita, T.; Fujikawa, K.; Dobashi, H.; Susaki, K. A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease. Mod. Rheumatol. 2017, 27, 849–854. [Google Scholar] [CrossRef]
- Sasaki, T.; Akiyama, M.; Kaneko, Y.; Takeuchi, T. Immunoglobulin G4-related disease and idiopathic multicentric Castleman’s disease: Confusable immune-mediated disorders. Rheumatology 2022, 61, 490–501. [Google Scholar] [CrossRef]
- Otani, K.; Inoue, D.; Fujikura, K.; Komori, T.; Abe-Suzuki, S.; Tajiri, T.; Itoh, T.; Zen, Y. Idiopathic multicentric Castleman’s disease: A clinicopathologic study in comparison with IgG4-related disease. Oncotarget 2018, 9, 6691. [Google Scholar] [CrossRef]
- Sato, Y.; Kojima, M.; Takata, K.; Morito, T.; Mizobuchi, K.; Tanaka, T.; Inoue, D.; Shiomi, H.; Iwao, H.; Yoshino, T. Multicentric Castleman’s disease with abundant IgG4-positive cells: A clinical and pathological analysis of six cases. J. Clin. Pathol. 2010, 63, 1084–1089. [Google Scholar] [CrossRef]
- Kojima, M.; Nakamura, N.; Tsukamoto, N.; Otuski, Y.; Shimizu, K.; Itoh, H.; Kobayashi, S.; Kobayashi, H.; Murase, T.; Masawa, N. Clinical implications of idiopathic multicentric castleman disease among Japanese: A report of 28 cases. Int. J. Surg. Pathol. 2008, 16, 391–398. [Google Scholar] [CrossRef] [PubMed]
- Xu, D.; Lv, J.; Dong, Y.; Wang, S.; Su, T.; Zhou, F.; Zou, W.; Zhao, M.; Zhang, H. Renal involvement in a large cohort of Chinese patients with Castleman disease. Nephrol. Dial. Transplant. 2012, 27 (Suppl. 3), iii119–iii125. [Google Scholar] [CrossRef] [PubMed]
- El Karoui, K.; Vuiblet, V.; Dion, D.; Izzedine, H.; Guitard, J.; Frimat, L.; Delahousse, M.; Remy, P.; Boffa, J.-J.; Pillebout, E. Renal involvement in Castleman disease. Nephrol. Dial. Transplant. 2011, 26, 599–609. [Google Scholar] [CrossRef] [PubMed]
- Saeki, T.; Kawano, M. IgG4-related kidney disease. Kidney Int. 2014, 85, 251–257. [Google Scholar] [CrossRef] [PubMed]
- Yuan, X.-G.; Hu, W.; Chen, F.-F.; Huang, B.-F.; Zhao, X.-Y. Renal complications of Castleman’s disease: Report of two cases and analysis of 75 cases. Clin. Exp. Nephrol. 2011, 15, 921–926. [Google Scholar] [CrossRef]
- Saiki, R.; Katayama, K.; Hirabayashi, Y.; Oda, K.; Fujimoto, M.; Murata, T.; Nakajima, A.; Dohi, K. Membranous nephropathy associated with multicentric Castleman’s disease that was successfully treated with tocilizumab: A case report and review of the literature. BMC Nephrol. 2021, 22, 216. [Google Scholar] [CrossRef]
- Masaki, Y.; Dong, L.; Kurose, N.; Kitagawa, K.; Morikawa, Y.; Yamamoto, M.; Takahashi, H.; Shinomura, Y.; Imai, K.; Saeki, T. Proposal for a new clinical entity, IgG4-positive multi-organ lymphoproliferative syndrome: Analysis of 64 cases of IgG4-related disorders. Ann. Rheum. Dis. 2008, 68, 1310–1315. [Google Scholar] [CrossRef] [PubMed]
- Sasaki, T.; Akiyama, M.; Kaneko, Y.; Mori, T.; Yasuoka, H.; Suzuki, K.; Yamaoka, K.; Okamoto, S.; Takeuchi, T. Distinct features distinguishing IgG4-related disease from multicentric Castleman’s disease. RMD Open 2017, 3, e000432. [Google Scholar] [CrossRef]
- Zoshima, T.; Yamada, K.; Hara, S.; Mizushima, I.; Yamagishi, M.; Harada, K.; Sato, Y.; Kawano, M. Multicentric Castleman Disease With Tubulointerstitial Nephritis Mimicking IgG4-related Disease: Two Case Reports. Am. J. Surg. Pathol. 2016, 40, 495–501. [Google Scholar] [CrossRef]
- Izumi, Y.; Takeshita, H.; Moriwaki, Y.; Hisatomi, K.; Matsuda, M.; Yamashita, N.; Kawahara, C.; Shigemitsu, Y.; Iwanaga, N.; Kawakami, A.; et al. Multicentric Castleman disease mimicking IgG4-related disease: A case report. Mod. Rheumatol. 2017, 27, 174–177. [Google Scholar] [CrossRef] [PubMed]
- Mochizuki, H.; Kato, M.; Higuchi, T.; Koyamada, R.; Arai, S.; Okada, S.; Eto, H. Overlap of IgG4-related disease and multicentric Castleman’s disease in a patient with skin lesions. Intern. Med. 2017, 56, 1095–1099. [Google Scholar] [CrossRef]
- Satou, A.; Notohara, K.; Zen, Y.; Nakamura, S.; Yoshino, T.; Okazaki, K.; Sato, Y. Clinicopathological differential diagnosis of IgG4-related disease: A historical overview and a proposal of the criteria for excluding mimickers of IgG4-related disease. Pathol. Int. 2020, 70, 391–402. [Google Scholar] [CrossRef]
- Nishikori, A.; Nishimura, M.F.; Nishimura, Y.; Notohara, K.; Satou, A.; Moriyama, M.; Nakamura, S.; Sato, Y. Investigation of IgG4-positive cells in idiopathic multicentric Castleman disease and validation of the 2020 exclusion criteria for IgG4-related disease. Pathol. Int. 2022, 72, 43–52. [Google Scholar] [CrossRef]
Blood Count | Biochemistry | Immunology | ||||||
---|---|---|---|---|---|---|---|---|
WBC | 7500 | /μL | TP | 10.9 | g/dL | IgG | 7132 | mg/dL |
RBC | 324 × 104 | /μL | Alb | 2.5 | g/dL | IgG4 | 2130 | mg/dL |
Hb | 8.7 | g/dL | AST | 11 | U/L | IgA | 238 | mg/dL |
Plt | 27.1 × 104 | /μL | ALT | 8 | U/L | IgM | 93 | mg/dL |
ESR | 80 | mm/h | BUN | 28 | mg/dL | C3 | 99 | mg/dL |
Cr | 1.96 | mg/dL | C4 | 16 | mg/dL | |||
Urinalysis | eGFR | 29.4 | mL/min/1.73 m2 | ANA | 40 | times | ||
Specific gravity | 1.011 | UA | 9.8 | mg/dL | M protein | (-) | ||
pH | 5.5 | Na | 135 | mEq/L | sIL-2R | 3991 | U/mL | |
Sugar | (-) | Cl | 106 | mEq/L | Amyloid A | 35 | mg/L | |
Proteinuria | (±) | K | 4.7 | mEq/L | IL-6 | 21.1 | pg/mL | |
Occult blood | (±) | CRP | 4.98 | mg/dL | VEGF | 1044.4 | pg/mL | |
Sediment RBC | 1–4 | /HPF | Fe | 26 | μg/dL | HHV-8 | (-) | |
Urinary Protein | 0.44 | g/gCr | TIBC | 188 | μg/dL | |||
NAG | 11.9 | IU/L | ferritin | 92 | ng/mL | |||
β2MG | 3406 | μg/L | ||||||
BJP | (-) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sawada, E.; Shioda, Y.; Ogawa, K.; Iwashita, T.; Ono, Y.; Hasegawa, H.; Maeshima, A. A Case of Castleman’s Disease with a Marked Infiltration of IgG4-Positive Cells in the Renal Interstitium. Diagnostics 2024, 14, 476. https://doi.org/10.3390/diagnostics14050476
Sawada E, Shioda Y, Ogawa K, Iwashita T, Ono Y, Hasegawa H, Maeshima A. A Case of Castleman’s Disease with a Marked Infiltration of IgG4-Positive Cells in the Renal Interstitium. Diagnostics. 2024; 14(5):476. https://doi.org/10.3390/diagnostics14050476
Chicago/Turabian StyleSawada, Erika, Yuya Shioda, Kohki Ogawa, Takatsugu Iwashita, Yuko Ono, Hajime Hasegawa, and Akito Maeshima. 2024. "A Case of Castleman’s Disease with a Marked Infiltration of IgG4-Positive Cells in the Renal Interstitium" Diagnostics 14, no. 5: 476. https://doi.org/10.3390/diagnostics14050476